Exelixis (EXEL) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Exelixis (EXEL) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 14.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 14.72% |
| Apr 3, 2026 | 31.86% |
| Jan 2, 2026 | 74.84% |
| Oct 3, 2025 | 64.09% |
| Jul 4, 2025 | -18.25% |
| Apr 4, 2025 | 327.73% |
| Jan 3, 2025 | 63.55% |
| Sep 27, 2024 | 11,232.66% |
| Jun 28, 2024 | 178.54% |
| Mar 29, 2024 | -6.77% |
| Dec 29, 2023 | 383.43% |
| Sep 29, 2023 | -98.58% |
| Jun 30, 2023 | 14.87% |
| Mar 31, 2023 | -41.63% |
| Dec 30, 2022 | -131.71% |
| Sep 30, 2022 | 91.63% |
| Jul 1, 2022 | -26.45% |
| Apr 1, 2022 | 4,183.14% |
| Dec 31, 2021 | 167.74% |
| Oct 1, 2021 | 219.24% |